Shanghai Institute ofDigestive Disease

ShanghaiInstitute of Digestive Disease (SIDD) was founded in 1984. Sincethen SIDD has developed arduously and extensively by conforming inthe motto of “Austerity, Practicality, Unity and Creativity”, andhas become one of the top research institutes in CHINA. SIDD has astaff of more than 100, including 8 professors and 10 associatedprofessors. At SIDD, there are two research divisions,Gastroenterology and Hepatology, and several laboratories, i.e.molecular pathology, cell biology, molecular biology, biochemistry,immunology, gut hormones, gastrointerstinalphysiology,pharmacology, microbiology (Parvovirus H-1 and H.pylori), flow cytometry. The endoscopy center was established onthis year. The research interest is mainly focused on chronicgastric disease and chronic liver disease. About 50 grants weregained and 30 prizes of science and technology were awarded fromthe State, the Ministry of Public Health and/or the Shanghaimunicipality in the past ten years. More than 400 papers and 20books were published in English and Chinese. Over 100 studentsstudied for Ph.D. or master’s degree have completed theirtraining courses and research programs. In each year more than 30physicians come from all over China are accepted for the advancedtraining on hepato-gasteroenterology atSIDD.


145 Middle Shandong Road,Shanghai 200001,China (ShanghaiJiao-Tong Univ School of Medicine Renji Hospital)






Dr.Fang graduated from Jining Medical College of Medicineon 1984, got a Master degree from Nanjing TCM University on July1990, and received his Ph.D and M.D.degrees from Shanghai SecondMedical University on July 1996. He worked at GI Division,University of Connecticut Health Center, USA as a visiting scholarfrom Sept 1998 to July1999, he also worked at NCI/NIH,USA from Aug1999 to Oct 2001; he was a research fellow in Cancer Center,University of Michigan at Ann Arbor, USA on 2004.


His group focuses upon the studies about epigeneticmodification and cell signaling pathway during GI carcinogenesis.They perform preclinical investigations in cell, molecular, andanimal models, and in early phase human clinical trials. Their overall goal is to prevent the formation of human GI cancermetastasis, and thus death from GI cancer.


1. got BEST PAPER PRIZE at 1996 Shanghai InternationalConference ofGastroenterology; 

2.< effect of folic acid and butyrate on thetumorigenesis and prevention of gi cancer> received The SecondPrize for China's 2008 State Scientific and Technological ProgressAwards


1. Xiong H, Chen ZF, Liang QC, Du W, Chen HM, Su WY, HanZG, Chen GQ, Fang JY(Corresponding author). Inhibition of DNAmethyltransferase induces G2 cell cycle arrest and apoptosis inhuman colorectal cancer cells via inhibition of JAK2/STAT3/STAT5signaling. J Cell Mol Med, 2009; Jan 16. PMID: 19175468

2. Xiong H, Zhang ZG, Tian XQ, Sun DF, Zhang YJ, Lu R, Liang QC,Chen YX, Fang JY(Corresponding author). Inhibition of JAK1, JAK2and STAT3 signaling induces apoptosis, cell cycle arrest andreduces tumor cell invasion in colorectal cancer cells. Neoplasia,2008;10:287-97

3. Lu R, Wang X, Chen ZF, Sun DF, Tian XQ, Fang JY(Correspondingauthor). Inhibition of the extracellular signal-regulatedkinase/mitogen-activated protein kinase pathway decrease DNAmethylation in colon cancer cells. J Biol Chem, 2007;282:12249-59

4. Fang JY(Corresponding author), Lu R, Mikovits JA, Cheng ZH, ZhuHY, Chen YX,Lu LG. Recombinant DNA methyltransferase 1 constructsregulate expression of hMSH2 and hMLH1 in human colon cancer cellline SW1116. Cancer Lett,2006;233:217-25

5. Fang JY(Corresponding author), Richardson BC. The extracellularsignal regulated kinase- mitogen-activated protein kinasessignaling pathway and human colorectal cancer. Lancet Oncol,2005;6:322-7